References
1. Scarinci, F., et al., Central chorioretinopathy associated with topical use of minoxidil 2% for treatment of baldness. Cutaneous and ocular toxicology, 2012. 31 (2): p. 157-159.
2. Liu, B., T. Deng, and J. Zhang, Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis. Retina, 2016.36 (1): p. 9-19.
3. Iacono, P., et al., Pharmacotherapy of Central Serous Chorioretinopathy: A Review of the Current Treatments. Current pharmaceutical design, 2018. 24 (41): p. 4864-4873.
4. Hanumunthadu, D., et al., Management of chronic central serous chorioretinopathy. Indian journal of ophthalmology, 2018.66 (12): p. 1704.
5. Iijima, H., et al., Plasminogen activator inhibitor 1 in central serous chorioretinopathy. American journal of ophthalmology, 1999. 127 (4): p. 477-478.
6. Satoh, H., et al., A case of acute myocardial infarction associated with topical use of minoxidil (RiUP®) for treatment of baldness. Japanese heart journal, 2000. 41 (4): p. 519-523.
7. Rastmanesh, R., Alopecia and ocular alterations: a role for Minoxidil? Journal of Receptors and Signal Transduction, 2010.30 (3): p. 189-192.
8. Venkatesh, R., et al., Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone–a case report. BMC Ophthalmology, 2020. 20 (1): p. 1-5.
Figure Legends